Plus   Neg

Moody's Guides FY20 In Line With Estimates; Boosts Dividend 12% - Quick Facts

While reporting financial results for the fourth quarter on Wednesday, Moody's Corp. (MCO) initiated its adjusted earnings and revenue growth guidance for the full-year 2020.

For fiscal 2020, the company now expects earnings in a range of $8.60 to $8.80 per share and adjusted earnings in the range of $9.10 to $9.30 per share on projected revenue growth in the mid-single-digit percent range.

On average, analysts polled by Thomson Reuters expect earnings of $9.12 per share on revenue growth of 6.1 percent to $5.10 billion for the year. Analysts' estimates typically exclude special items.

"For 2020, we expect to continue leveraging the capabilities of our core businesses, further innovate with new technologies and capitalize on strategic investments, such as our recently announced acquisition of Regulatory DataCorp.," said Raymond McDaniel, President and CEO.

Further, the company's Board of Directors also declared a 12 percent higher quarterly dividend of $0.56 per share of Moody's common stock, payable on March 18, 2020 to stockholders of record at the close of business on February 25, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT